Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius’ portfolio from 29 marketed and pipeline molecules today to up to 66 in the next ...
Das Portfolio der nächsten Generation erstreckt sich über 13 Therapiegebiete und verschiedene biologische Technologien, darunter monoklonale und bispezifische Antikörper, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results